These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29512735)

  • 41. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
    Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease.
    Rabban JT; Glidden D; Kwan ML; Chen YY
    Am J Surg Pathol; 2009 Feb; 33(2):256-63. PubMed ID: 18936689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Utility of initial MRI for predicting extent of residual disease after neoadjuvant chemotherapy: analysis of 70 breast cancer patients.
    Murata Y; Ogawa Y; Yoshida S; Kubota K; Itoh S; Fukumoto M; Nishioka A; Moriki T; Maeda H; Tanaka Y
    Oncol Rep; 2004 Dec; 12(6):1257-62. PubMed ID: 15547747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effectiveness of mammary scintigraphy for determining the results of neoadjuvant polychemotherapy in breast cancer].
    Kanaev SV; Krivorot'ko PV; Novikov SN; Semiglazov VF; Semiglzova TIu; Turkevich EA; Zhukova LA; Klimashevskiĭ VF; Ivantsov AO; Donskikh RV; Klimenko VV; Briantseva ZhV
    Vopr Onkol; 2013; 59(3):328-33. PubMed ID: 23909033
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.
    Partridge SC; Gibbs JE; Lu Y; Esserman LJ; Sudilovsky D; Hylton NM
    AJR Am J Roentgenol; 2002 Nov; 179(5):1193-9. PubMed ID: 12388497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histologic sections.
    Tot T
    Cancer; 2007 Dec; 110(11):2551-60. PubMed ID: 17932896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
    Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
    J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy.
    Belli P; Costantini M; Malaspina C; Magistrelli A; LaTorre G; Bonomo L
    Clin Radiol; 2006 Nov; 61(11):946-53. PubMed ID: 17018307
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging.
    Abraham DC; Jones RC; Jones SE; Cheek JH; Peters GN; Knox SM; Grant MD; Hampe DW; Savino DA; Harms SE
    Cancer; 1996 Jul; 78(1):91-100. PubMed ID: 8646731
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer.
    Vriens BE; de Vries B; Lobbes MB; van Gastel SM; van den Berkmortel FW; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Smidt ML; Peer PG; Aarts MJ; Tjan-Heijnen VC;
    Eur J Cancer; 2016 Jan; 52():67-76. PubMed ID: 26650831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Accuracy of Posttreatment Imaging for Evaluation of Residual in Breast Disease After Neoadjuvant Endocrine Therapy.
    Zhang C; Kosiorek HE; Patel BK; Pockaj BA; Ahmad SB; Cronin PA
    Ann Surg Oncol; 2022 Oct; 29(10):6207-6212. PubMed ID: 35831526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
    Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
    Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy.
    Straver ME; Loo CE; Rutgers EJ; Oldenburg HS; Wesseling J; Vrancken Peeters MJ; Gilhuijs KG
    Ann Surg; 2010 Apr; 251(4):701-7. PubMed ID: 20224378
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
    Santamaría G; Bargalló X; Fernández PL; Farrús B; Caparrós X; Velasco M
    Radiology; 2017 Jun; 283(3):663-672. PubMed ID: 27875106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.
    Bufi E; Belli P; Costantini M; Cipriani A; Di Matteo M; Bonatesta A; Franceschini G; Terribile D; Mulé A; Nardone L; Bonomo L
    Clin Breast Cancer; 2015 Oct; 15(5):370-80. PubMed ID: 25891905
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer.
    Shien T; Akashi-Tanaka S; Miyakawa K; Hojo T; Shimizu C; Seki K; Ando M; Kohno T; Taira N; Doihara H; Katsumata N; Fujiwara Y; Kinoshita T
    World J Surg; 2009 Jan; 33(1):44-51. PubMed ID: 18953600
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Primary systemic therapy in breast cancer patients (2007-2010)].
    Zapf I; Tizedes G; Pavlovics G; Kovács G; Kálmán E; Szalai G; Kövér E; Farkas R; Horváth OP
    Magy Seb; 2011 Oct; 64(5):223-8. PubMed ID: 21997525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.